{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:05:44Z","timestamp":1772136344099,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-27481-0","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:14:08Z","timestamp":1765538048000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Virological characterization of SARS-CoV-2 BA.2.86 variants by assessing antiviral susceptibility, in vivo infectivity and replicative fitness"],"prefix":"10.1038","volume":"15","author":[{"given":"Emilie","family":"Giraud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9raldine","family":"Piorkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-S\u00e9lim","family":"Driouich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orn\u00e9llie","family":"Bernadin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrielle","family":"Durand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Gilles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rayane","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"van der Werf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"de Lamballerie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Agou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Nougair\u00e8de","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Touret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"27481_CR1","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.cell.2021.02.033","volume":"184","author":"P Supasa","year":"2021","unstructured":"Supasa, P. et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine Sera. Cell 184, 2201\u20132211e7 (2021).","journal-title":"Cell"},{"key":"27481_CR2","doi-asserted-by":"publisher","unstructured":"Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science https:\/\/doi.org\/10.1126\/science.abg3055 (2021).","DOI":"10.1126\/science.abg3055"},{"key":"27481_CR3","first-page":"e00850","volume":"0","author":"F Touret","year":"2021","unstructured":"Touret, F. et al. Replicative fitness of a SARS-CoV-2 20I\/501Y.V1 variant from lineage B.1.1.7 in human reconstituted bronchial epithelium. mBio 0, e00850\u2013e00821 (2021).","journal-title":"mBio"},{"key":"27481_CR4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41586-021-04245-0","volume":"602","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. Nature 602, 294\u2013299 (2022).","journal-title":"Nature"},{"key":"27481_CR5","doi-asserted-by":"publisher","unstructured":"Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. d41586-021-03827-2 https:\/\/doi.org\/10.1038\/d41586-021-03827-2 (2021).","DOI":"10.1038\/d41586-021-03827-2"},{"key":"27481_CR6","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41564-022-01143-7","volume":"7","author":"BJ Willett","year":"2022","unstructured":"Willett, B. J. et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat. Microbiol. 7, 1161\u20131179 (2022).","journal-title":"Nat. Microbiol."},{"key":"27481_CR7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657\u2013663 (2022).","journal-title":"Nature"},{"key":"27481_CR8","doi-asserted-by":"publisher","unstructured":"Cao, Y. et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. 1\u20133 https:\/\/doi.org\/10.1038\/s41586-022-05644-7 (2022).","DOI":"10.1038\/s41586-022-05644-7"},{"key":"27481_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-023-06753-7","volume":"625","author":"A Yisimayi","year":"2024","unstructured":"Yisimayi, A. et al. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Nature 625, 148\u2013156 (2024).","journal-title":"Nature"},{"key":"27481_CR10","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/s41586-024-08315-x","volume":"637","author":"F Jian","year":"2025","unstructured":"Jian, F. et al. Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1. Nature 637, 921\u2013929 (2025).","journal-title":"Nature"},{"key":"27481_CR11","doi-asserted-by":"publisher","first-page":"109904","DOI":"10.1016\/j.isci.2024.109904","volume":"27","author":"L Zhang","year":"2024","unstructured":"Zhang, L. et al. Rapid spread of the SARS-CoV-2 JN.1 lineage is associated with increased neutralization evasion. iScience 27, 109904 (2024).","journal-title":"iScience"},{"key":"27481_CR12","doi-asserted-by":"publisher","first-page":"112443","DOI":"10.1016\/j.celrep.2023.112443","volume":"42","author":"P Qu","year":"2023","unstructured":"Qu, P. et al. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants. Cell. Rep. 42, 112443 (2023).","journal-title":"Cell. Rep."},{"key":"27481_CR13","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1038\/s41467-024-46490-7","volume":"15","author":"D Planas","year":"2024","unstructured":"Planas, D. et al. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86\/JN.1 lineages combining increased fitness and antibody evasion. Nat. Commun. 15, 2254 (2024).","journal-title":"Nat. Commun."},{"key":"27481_CR14","doi-asserted-by":"publisher","first-page":"e509","DOI":"10.1016\/S1473-3099(23)00682-5","volume":"23","author":"R Lassauni\u00e8re","year":"2023","unstructured":"Lassauni\u00e8re, R. et al. Virus isolation and neutralisation of SARS-CoV-2 variants BA.2.86 and EG.5.1. Lancet Infect. Dis. 23, e509\u2013e510 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"27481_CR15","doi-asserted-by":"publisher","first-page":"106413","DOI":"10.1016\/j.isci.2023.106413","volume":"26","author":"F Touret","year":"2023","unstructured":"Touret, F. et al. Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 Omicron sub-lineages. iScience 26, 106413 (2023).","journal-title":"iScience"},{"key":"27481_CR16","doi-asserted-by":"publisher","first-page":"105137","DOI":"10.1016\/j.antiviral.2021.105137","volume":"193","author":"F Touret","year":"2021","unstructured":"Touret, F. et al. Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2. Antiviral Res. 193, 105137 (2021).","journal-title":"Antiviral Res."},{"key":"27481_CR17","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41586-023-06487-6","volume":"621","author":"A Addetia","year":"2023","unstructured":"Addetia, A. et al. Neutralization, effector function and immune imprinting of Omicron variants. Nature 621, 592\u2013601 (2023).","journal-title":"Nature"},{"key":"27481_CR18","doi-asserted-by":"publisher","first-page":"105638","DOI":"10.1016\/j.antiviral.2023.105638","volume":"215","author":"JS Driouich","year":"2023","unstructured":"Driouich, J. S., Bernadin, O., Touret, F., de Lamballerie, X. & Nougair\u00e8de, A. Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model. Antiviral Res. 215, 105638 (2023).","journal-title":"Antiviral Res."},{"key":"27481_CR19","doi-asserted-by":"publisher","first-page":"e16664","DOI":"10.1016\/j.heliyon.2023.e16664","volume":"9","author":"C H\u00e9rate","year":"2023","unstructured":"H\u00e9rate, C. et al. Sotrovimab retains activity against SARS-CoV-2 Omicron variant BQ.1.1 in a non-human primate model. Heliyon 9, e16664 (2023).","journal-title":"Heliyon"},{"key":"27481_CR20","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1038\/s41591-022-01792-5","volume":"28","author":"T Bruel","year":"2022","unstructured":"Bruel, T. et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat. Med. 28, 1297\u20131302 (2022).","journal-title":"Nat. Med."},{"key":"27481_CR21","doi-asserted-by":"publisher","first-page":"12609","DOI":"10.1038\/s41598-022-16964-z","volume":"12","author":"F Touret","year":"2022","unstructured":"Touret, F. et al. In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5. Sci. Rep. 12, 12609 (2022).","journal-title":"Sci. Rep."},{"key":"27481_CR22","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2023.12.025","volume":"187","author":"L Zhang","year":"2024","unstructured":"Zhang, L. et al. SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency. Cell 187, 596\u2013608e17 (2024).","journal-title":"Cell"},{"key":"27481_CR23","doi-asserted-by":"publisher","first-page":"105814","DOI":"10.1016\/j.antiviral.2024.105814","volume":"222","author":"HS Bouzidi","year":"2024","unstructured":"Bouzidi, H. S. et al. Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains. Antiviral Res. 222, 105814 (2024).","journal-title":"Antiviral Res."},{"key":"27481_CR24","doi-asserted-by":"publisher","unstructured":"Sama, B. et al. The effects of remdesivir\u2019s functional groups on its antiviral potency and resistance against the SARS-CoV-2 polymerase. Antiviral Res. 106034 https:\/\/doi.org\/10.1016\/j.antiviral.2024.106034 (2024).","DOI":"10.1016\/j.antiviral.2024.106034"},{"key":"27481_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa325","author":"JFW Chan","year":"2020","unstructured":"Chan, J. F. W. et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa325 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"27481_CR26","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/s41467-021-21992-w","volume":"12","author":"JS Driouich","year":"2021","unstructured":"Driouich, J. S. et al. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model. Nat. Commun. 12, 1735 (2021).","journal-title":"Nat. Commun."},{"key":"27481_CR27","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1126\/science.abn8939","volume":"377","author":"S Yuan","year":"2022","unstructured":"Yuan, S. et al. Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters. Science 377, 428\u2013433 (2022).","journal-title":"Science"},{"key":"27481_CR28","doi-asserted-by":"publisher","first-page":"116988","DOI":"10.1016\/j.biopha.2024.116988","volume":"177","author":"JS Driouich","year":"2024","unstructured":"Driouich, J. S. et al. Preclinical in vivo assessment of the activity of AZD7442 anti-SARS-CoV-2 monoclonal antibodies against Omicron sublineages. Biomed. Pharmacother. 177, 116988 (2024).","journal-title":"Biomed. Pharmacother"},{"key":"27481_CR29","doi-asserted-by":"publisher","first-page":"105253","DOI":"10.1016\/j.antiviral.2022.105253","volume":"198","author":"R Abdelnabi","year":"2022","unstructured":"Abdelnabi, R. et al. The Omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters. Antiviral Res. 198, 105253 (2022).","journal-title":"Antiviral Res."},{"key":"27481_CR30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/v16010122","volume":"16","author":"R Abdelnabi","year":"2024","unstructured":"Abdelnabi, R., Lassauni\u00e8re, R., Maes, P., Weynand, B. & Neyts, J. Comparing the infectivity of recent SARS-CoV-2 Omicron sub-variants in Syrian hamsters. Viruses 16, 122 (2024).","journal-title":"Viruses"},{"key":"27481_CR31","doi-asserted-by":"publisher","first-page":"100059","DOI":"10.1016\/j.xcrm.2020.100059","volume":"1","author":"A Pizzorno","year":"2020","unstructured":"Pizzorno, A. et al. Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia. Cell. Rep. Med. 1, 100059 (2020).","journal-title":"Cell. Rep. Med."},{"key":"27481_CR32","doi-asserted-by":"publisher","unstructured":"Plante, J. A. et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 1\u20136 https:\/\/doi.org\/10.1038\/s41586-020-2895-3 (2020).","DOI":"10.1038\/s41586-020-2895-3"},{"key":"27481_CR33","doi-asserted-by":"publisher","first-page":"e1004738","DOI":"10.1371\/journal.ppat.1004738","volume":"11","author":"L de Fabritus","year":"2015","unstructured":"de Fabritus, L., Nougair\u00e8de, A., Aubry, F., Gould, E. A. & de Lamballerie, X. Attenuation of tick-borne encephalitis virus using large-scale random codon re-encoding. PLoS Pathog. 11, e1004738 (2015).","journal-title":"PLoS Pathog"},{"key":"27481_CR34","doi-asserted-by":"publisher","first-page":"8728","DOI":"10.1038\/s41467-024-53033-7","volume":"15","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86\/JN.1 and EG.5.1\/HK.3. Nat. Commun. 15, 8728 (2024).","journal-title":"Nat. Commun."},{"key":"27481_CR35","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.chom.2024.01.001","volume":"32","author":"T Tamura","year":"2024","unstructured":"Tamura, T. et al. Virological characteristics of the SARS-CoV-2 BA.2.86 variant. Cell. Host Microbe. 32, 170\u2013180e12 (2024).","journal-title":"Cell. Host Microbe"},{"key":"27481_CR36","doi-asserted-by":"publisher","first-page":"eado2817","DOI":"10.1126\/scitranslmed.ado2817","volume":"16","author":"Y Cai","year":"2024","unstructured":"Cai, Y. et al. AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults. Sci. Transl Med. 16, eado2817 (2024).","journal-title":"Sci. Transl Med."},{"key":"27481_CR37","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41586-022-04441-6","volume":"603","author":"PJ Halfmann","year":"2022","unstructured":"Halfmann, P. J. et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603, 687\u2013692 (2022).","journal-title":"Nature"},{"key":"27481_CR38","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41586-022-04474-x","volume":"603","author":"B Meng","year":"2022","unstructured":"Meng, B. et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature 603, 706\u2013714 (2022).","journal-title":"Nature"},{"key":"27481_CR39","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280e8 (2020).","journal-title":"Cell"},{"key":"27481_CR40","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41467-025-55938-3","volume":"16","author":"A Wickenhagen","year":"2025","unstructured":"Wickenhagen, A. et al. Evolution of Omicron lineage towards increased fitness in the upper respiratory tract in the absence of severe lung pathology. Nat. Commun. 16, 594 (2025).","journal-title":"Nat. Commun."},{"key":"27481_CR41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41564-024-01878-5","volume":"10","author":"W Furnon","year":"2025","unstructured":"Furnon, W. et al. Phenotypic evolution of SARS-CoV-2 spike during the COVID-19 pandemic. Nat. Microbiol. 10, 77\u201393 (2025).","journal-title":"Nat. Microbiol."},{"key":"27481_CR42","doi-asserted-by":"publisher","first-page":"2300740","DOI":"10.2807\/1560-7917.ES.2024.29.2.2300740","volume":"29","author":"LM Jeworowski","year":"2024","unstructured":"Jeworowski, L. M. et al. Humoral immune escape by current SARS-CoV-2 variants BA.2.86 and JN.1, December 2023. Eurosurveillance 29, 2300740 (2024).","journal-title":"Eurosurveillance"},{"key":"27481_CR43","doi-asserted-by":"publisher","unstructured":"Yang, X. et al. Immune escape of BA. 2.86 is comparable to XBB subvariants from the plasma of BA.5- and BA.5\u2010XBB\u2010convalescent subpopulations. J. Med. Virol. https:\/\/doi.org\/10.1002\/jmv.29417 (2024).","DOI":"10.1002\/jmv.29417"},{"key":"27481_CR44","doi-asserted-by":"publisher","first-page":"13093","DOI":"10.1038\/s41598-020-70143-6","volume":"10","author":"F Touret","year":"2020","unstructured":"Touret, F. et al. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci. Rep. 10, 13093 (2020).","journal-title":"Sci. Rep."},{"key":"27481_CR45","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.antiviral.2019.05.005","volume":"168","author":"F Touret","year":"2019","unstructured":"Touret, F. et al. Phylogenetically based establishment of a dengue virus panel, representing all available genotypes, as a tool in dengue drug discovery. Antiviral Res. 168, 109\u2013113 (2019).","journal-title":"Antiviral Res."},{"key":"27481_CR46","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1038\/s41598-022-08559-5","volume":"12","author":"F Touret","year":"2022","unstructured":"Touret, F., Baronti, C., Bouzidi, H. S. & de Lamballerie, X. In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate. Sci. Rep. 12, 4683 (2022).","journal-title":"Sci. Rep."},{"key":"27481_CR47","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed, L. J. & Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27, 493\u2013497 (1938).","journal-title":"Am. J. Epidemiol."},{"key":"27481_CR48","doi-asserted-by":"crossref","unstructured":"Petit, P. R. et al. Further preclinical characterization of molnupiravir against SARS-CoV-2: antiviral activity determinants and viral genome alteration patterns. Heliyon. 10 (2024).","DOI":"10.2139\/ssrn.4735572"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27481-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27481-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27481-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:14:09Z","timestamp":1765538049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27481-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["27481"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-27481-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6962851\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In vivo experiments were approved by the local ethical committee (C2EA\u201414) and the French \u201cMinist\u00e8re de l\u2019Enseignement Sup\u00e9rieur, de la Recherche et de l\u2019Innovation\u201d (APAFIS#35014). This study was conducted according to ARRIVE guidelines (\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43715"}}